PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer.

Abstract In patients with differentiated thyroid cancer, stimulated thyroglobulin (sTg) levels after thyroid hormone withdrawal (THW) at remnant ablation (RA) and at 6 to 12 months are known to have good prognostic value. This study aimed to evaluate the prognostic impacts and best cutoff values of sTg levels under recombinant human thyroid stimulating hormone (rhTSH) treatment at RA and at follow-up. A total of 151 patients were enrolled, of whom 77 were followed up with rhTSH-stimulated Tg (rhTSH-sTg) and 74 with THW-stimulated Tg (THW-sTg) at 6 to 12 months after rhTSH-aided RA. Risk stratification, response to treatment (excellent, indeterminate, biochemical incomplete, and structural incomplete response [SIR]), and clinical outcome were accessed by revised American Thyroid Association (ATA) guideline criteria. Seven out of 151 (4.6%) patients were confirmed to have SIR during the median follow-up of 79.0 months; 3 in the rhTSH group and 4 in the THW group. One hundred thirty-two out of 151 (87.4%) patients were confirmed to have excellent response; 68 (51.5%) in the rhTSH group and 64 (48.5%) in the THW group. The cutoff values of sTg for predicting SIR to treatment at rhTSH-aided RA, THW-sTg, and rhTSH-sTg were 4.64 ng/mL (sensitivity 85.7%, specificity 76.4%, negative predictive value [NPV] 99.2%), 2.41 ng/mL (sensitivity 100%, specificity 94.3%, NPV 100%), and 1.02 ng/mL (sensitivity 66.7%, specificity 94.6%, NPV 98.6%), respectively. sTg levels using rhTSH at both RA and follow-up has a high NPV and are as effective as using THW for predicting SIR. The risk classification according to the revised ATA guidelines can be used effectively to supplement rhTSH-aided sTg levels to predict better clinical outcomes.
PMID
Related Publications

The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.

Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later.

Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.

Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.

Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28723762
OWN - NLM
STAT- MEDLINE
DA  - 20170720
DCOM- 20170728
LR  - 20170728
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 29
DP  - 2017 Jul
TI  - Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict
      structural incomplete response to treatment in patients with differentiated
      thyroid cancer.
PG  - e7512
LID - 10.1097/MD.0000000000007512 [doi]
AB  - In patients with differentiated thyroid cancer, stimulated thyroglobulin (sTg)
      levels after thyroid hormone withdrawal (THW) at remnant ablation (RA) and at 6
      to 12 months are known to have good prognostic value. This study aimed to
      evaluate the prognostic impacts and best cutoff values of sTg levels under
      recombinant human thyroid stimulating hormone (rhTSH) treatment at RA and at
      follow-up. A total of 151 patients were enrolled, of whom 77 were followed up
      with rhTSH-stimulated Tg (rhTSH-sTg) and 74 with THW-stimulated Tg (THW-sTg) at 6
      to 12 months after rhTSH-aided RA. Risk stratification, response to treatment
      (excellent, indeterminate, biochemical incomplete, and structural incomplete
      response [SIR]), and clinical outcome were accessed by revised American Thyroid
      Association (ATA) guideline criteria. Seven out of 151 (4.6%) patients were
      confirmed to have SIR during the median follow-up of 79.0 months; 3 in the rhTSH 
      group and 4 in the THW group. One hundred thirty-two out of 151 (87.4%) patients 
      were confirmed to have excellent response; 68 (51.5%) in the rhTSH group and 64
      (48.5%) in the THW group. The cutoff values of sTg for predicting SIR to
      treatment at rhTSH-aided RA, THW-sTg, and rhTSH-sTg were 4.64 ng/mL (sensitivity 
      85.7%, specificity 76.4%, negative predictive value [NPV] 99.2%), 2.41 ng/mL
      (sensitivity 100%, specificity 94.3%, NPV 100%), and 1.02 ng/mL (sensitivity
      66.7%, specificity 94.6%, NPV 98.6%), respectively. sTg levels using rhTSH at
      both RA and follow-up has a high NPV and are as effective as using THW for
      predicting SIR. The risk classification according to the revised ATA guidelines
      can be used effectively to supplement rhTSH-aided sTg levels to predict better
      clinical outcomes.
FAU - Ha, Jeonghoon
AU  - Ha J
AD  - aDivision of Endocrinology and Metabolism, Department of Internal Medicine
      bDepartment of Surgery, College of Medicine, The Catholic University of Korea,
      Korea.
FAU - Kim, Min Hee
AU  - Kim MH
FAU - Jo, Kwanhoon
AU  - Jo K
FAU - Lim, Yejee
AU  - Lim Y
FAU - Bae, Ja Seong
AU  - Bae JS
FAU - Lee, Sohee
AU  - Lee S
FAU - Kang, Moo Il
AU  - Kang MI
FAU - Cha, Bong Yun
AU  - Cha BY
FAU - Lim, Dong Jun
AU  - Lim DJ
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Recombinant Proteins)
RN  - 9002-71-5 (Thyrotropin)
RN  - 9010-34-8 (Thyroglobulin)
SB  - AIM
SB  - IM
MH  - Biomarkers, Tumor/blood
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Iodine Radioisotopes/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Recombinant Proteins/*administration & dosage
MH  - Risk
MH  - Sensitivity and Specificity
MH  - Thyroglobulin/*blood
MH  - Thyroid Neoplasms/*blood/*therapy
MH  - Thyrotropin/*administration & dosage
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2017/07/21 06:00
MHDA- 2017/07/29 06:00
CRDT- 2017/07/21 06:00
AID - 10.1097/MD.0000000000007512 [doi]
AID - 00005792-201707210-00027 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(29):e7512. doi: 10.1097/MD.0000000000007512.